Factual · Independent · Patient-First

Your path through
cancer's complexity.

Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention — all in plain English, all in one place. Browse anonymously. No account required.

450K+
Active clinical trials worldwide
21
Cancer types covered
100%
Fact-based, source-cited data
Free
Always free to browse. Always.
A person walking a lit path through a dark maze, surrounded by floating medical information — representing the journey through cancer treatment options.
🔒 You are browsing anonymously.  No account needed to access treatment data, trial listings, or guides. Create a free account only when you're ready — to save your profile and opt in to trial matching.
A NOTE BEFORE YOU BEGIN

If you're here, you're probably scared.
That's okay. You're in the right place.

You're likely here because you — or someone you love — has just been diagnosed with cancer. Maybe you've already spent hours searching the internet and found nothing but statistics that terrified you, medical jargon written for doctors, and information that left you more confused than when you started.

Your Cancer Path was built specifically for this moment. Every approved treatment, every open clinical trial, every promising drug in development — explained in plain English, sourced from the FDA and peer-reviewed research, and presented without judgment or agenda. No miracle cures. No hype. Just facts.

This is not a substitute for your oncologist. But it will help you walk into that office better informed, with better questions, and a clearer picture of every path available to you. That's all we're trying to do.

KF
The Founder
Your Cancer Path Founder · Prostate Cancer Survivor · 16 years cancer-free
How to use Your Cancer Path
1
Find your cancer type
Scroll down and click the cancer that applies. All 20 types are covered with full treatment and trial data.
2
Explore your options
Review approved treatments with real efficacy data. Browse live clinical trials. See promising drugs still in development.
3
Bring it to your doctor
Everything here is designed to help you have a better conversation with your oncologist — not replace them. Print it, save it, share it.
4
You're never alone here
Join our community to read real experiences from survivors. Ask questions. Offer support. Every post is reviewed before it goes live.
🔒 No account required. Browse everything anonymously. No email. No sign-up. No tracking.
Find your cancer type

Select a cancer type below to explore every approved treatment, open clinical trial, and promising investigational drug — in plain English.

🔍
🔵
Prostate Cancer
The most common cancer in men. Highly treatable when caught early, with many options from active surveillance to surgery, radiation, and hormone therapy.
🧪 47 open trials
💊 12 approved treatments
🟡
Breast Cancer
Affects men and women. Highly nuanced — treatment depends heavily on hormone receptor status, HER2 status, and stage. Leronlimab and others show promise.
🧪 89 open trials
💊 21 approved treatments
🔴
Colorectal Cancer
Third most common cancer in the US. Increasingly affecting younger adults. Significant advances in immunotherapy and targeted therapies in recent years.
🧪 62 open trials
💊 16 approved treatments
🫁
Lung Cancer
NSCLC and SCLC. One of the most rapidly evolving oncology landscapes — immunotherapy and targeted therapy have transformed outcomes.
🧪 5 open trials
💊 10 approved treatments
🟠
Pancreatic Cancer
One of the most challenging diagnoses. New KRAS-targeted drugs and mRNA vaccines entering trials offer real hope for the first time.
🧪 5 open trials
💊 6 approved treatments
🟣
Lymphoma
Hodgkin and Non-Hodgkin. CAR-T cell therapies have dramatically changed outcomes for many patients in just the past decade.
🧪 5 open trials
💊 8 approved treatments
🩸
Leukemia
ALL, AML, CLL, CML and subtypes. Targeted therapies and CAR-T have transformed survival rates across multiple types.
🧪 5 open trials
💊 7 approved treatments
🖤
Melanoma
Immunotherapy has produced the most dramatic and durable complete responses ever seen in oncology — 40%+ long-term survival in metastatic disease.
🧪 5 open trials
💊 6 approved treatments
🟤
Bladder Cancer
Immunotherapy, antibody-drug conjugates, and FGFR inhibitors have transformed advanced urothelial carcinoma treatment.
🧪 5 open trials
💊 7 approved treatments
🫀
Ovarian Cancer
PARP inhibitors for BRCA-mutated patients and mirvetuximab ADC have transformed advanced disease — first OS benefit over chemotherapy now demonstrated.
🧪 5 open trials
💊 7 approved treatments
🫘
Kidney Cancer
Immunotherapy combinations have transformed advanced RCC — 40%+ of patients now achieve durable responses including functional cures.
🧪 5 open trials
💊 7 approved treatments
🦋
Thyroid Cancer
Most types are highly curable. Selective RET inhibitors and BRAF+MEK combinations have transformed medullary and anaplastic subtypes.
🧪 5 open trials
💊 7 approved treatments
🧠
Brain Cancer
IDH-targeted vorasidenib (2024 approval) marks a major advance for low-grade glioma. Tumor treating fields and personalized vaccines are reshaping GBM.
🧪 5 open trials
💊 6 approved treatments
🫙
Liver Cancer
Atezolizumab + bevacizumab replaced sorafenib after 13 years as standard of care — immunotherapy combinations producing the first meaningful OS improvements.
🧪 5 open trials
💊 6 approved treatments
🟫
Uterine / Endometrial
Immunotherapy for dMMR/MSI-H tumors is dramatically extending survival. HER2-targeted therapy for serous subtype. The most common gynecologic cancer.
🧪 5 open trials
💊 6 approved treatments
🔵
Multiple Myeloma
CAR-T therapies achieving 98% response rates and bispecific antibodies available off-the-shelf — the most exciting treatment landscape in all of blood cancer.
🧪 5 open trials
💊 7 approved treatments
🫶
Cervical Cancer
Pembrolizumab and tisotumab vedotin ADC have both shown OS benefit in advanced disease. HPV vaccination prevents most cases entirely.
🧪 5 open trials
💊 5 approved treatments
Esophageal Cancer
HER2, PD-L1, and CLDN18.2 testing now mandatory. Immunotherapy combinations standard first-line for metastatic disease across all histologies.
🧪 5 open trials
💊 6 approved treatments
🫐
Gastric / Stomach Cancer
HER2, PD-L1, CLDN18.2, and MSI testing all guide treatment. Nivolumab + chemo and zolbetuximab + FOLFOX are new first-line standards.
🧪 5 open trials
💊 6 approved treatments
🩺
Head & Neck Cancer
HPV status and PD-L1 CPS score guide first-line therapy. Pembrolizumab now standard. Tisotumab vedotin and LAG-3 inhibitors in advanced trials.
🧪 5 open trials
💊 6 approved treatments
🫁
Mesothelioma
Rare but aggressive cancer of the pleura and peritoneum, almost always linked to asbestos exposure. Nivolumab + ipilimumab now the frontline standard. BAP1, NF2, and CDKN2A drive emerging targeted approaches.
🧪 6 open trials
💊 4 approved treatments

✅ All 21 cancer types are now live

Browse every cancer type above, or use the Explore page to find treatments, open trials, and promising drugs for any diagnosis.

Built by a survivor.
For survivors and fighters.
📋

Factual Only. No Opinions.

Every treatment, side effect, and efficacy rate is sourced from FDA approvals, peer-reviewed studies, and ClinicalTrials.gov. We cite everything. This site is primarily U.S.-focused — international visitors should verify approval status with their local regulatory authority.

🔒

Anonymous First

Browse everything without creating an account. No email required. No tracking. Your health search is your business alone.

🧪

Trials at Your Fingertips

Every open, enrolling clinical trial pulled directly from ClinicalTrials.gov — filtered, simplified, and explained in plain English.

🤝

Real Patient Voices

Our community is moderated by cancer survivors who've been through it. Every post is reviewed before publishing. Real experiences, verified.

Prostate Cancer
Approved treatments, clinical trials, and promising investigational drugs
Sort by
Filter side effects
Min efficacy
🔍
No results found Try a different drug name, company, or keyword.
Checking ClinicalTrials.gov for live data…
Sort by
Phase
🔍
No trials found Try searching by drug name, company, sponsor, or NCT trial ID.

⭐ What are "Promising Drugs"?

These are drugs that have shown meaningful results in clinical trials but have not yet received full FDA approval. They may be available through clinical trial enrollment, compassionate use, or Right to Try. All data is factual and sourced from published trial results.

Let the right trial find you.
Clinical trial sponsors are actively looking for patients exactly like you. By creating a free profile and checking the box below, you can raise your hand — and we'll connect sponsors to you directly, through our platform. You stay in control at all times.
⚠️ Trial matching with opt-in will be available when the full site launches. For now, you can find and contact trial sites directly using the Clinical Trials section above.

🗺️ How to read these pathways

Care pathways show the typical sequence of treatment decisions — from first-line options through salvage and escalation if earlier treatments stop working. These reflect how oncologists generally think about sequencing, not a prescription for any individual patient. Always discuss your specific situation with your care team.

Where do you want to start?

Select a cancer type to explore every approved treatment, open clinical trial, and promising investigational drug.

🔍
🔵
Prostate Cancer
Most common cancer in men. Multiple treatment paths from watchful waiting to surgery, radiation, hormone therapy, and immunotherapy.
🧪 47 open trials
💊 12 approved treatments
🟡
Breast Cancer
Treatment depends heavily on subtype — hormone receptor status, HER2, stage, and genetic markers like BRCA all shape options.
🧪 89 open trials
💊 21 approved treatments
🔴
Colorectal Cancer
Colon and rectal cancers. Significant recent advances with immunotherapy for MSI-H tumors and targeted KRAS inhibitors entering the landscape.
🧪 62 open trials
💊 16 approved treatments
🫁
Lung Cancer
NSCLC and SCLC. Molecular profiling now guides targeted therapy selection — EGFR, ALK, KRAS G12C, MET, and HER2 are all actionable.
🧪 5 open trials
💊 10 approved treatments
🟠
Pancreatic Cancer
Challenging but evolving. BRCA testing matters. KRAS inhibitors and personalized vaccines are entering trials for the first time.
🧪 5 open trials
💊 6 approved treatments
🟣
Lymphoma
Hodgkin and Non-Hodgkin. CAR-T, bispecific antibodies, and BTK inhibitors have transformed outcomes for relapsed/refractory disease.
🧪 5 open trials
💊 8 approved treatments
🩸
Leukemia
ALL, AML, CLL, CML and subtypes. Targeted therapies including venetoclax, menin inhibitors, and CAR-T have reshaped survival expectations.
🧪 5 open trials
💊 7 approved treatments
🖤
Melanoma
The immunotherapy success story. Combination checkpoint blockade produces 40%+ long-term survival in metastatic disease — unthinkable a decade ago.
🧪 5 open trials
💊 6 approved treatments
🟤
Bladder Cancer
Urothelial carcinoma. FGFR testing, Nectin-4 ADC therapy, and enfortumab + pembrolizumab have transformed first-line metastatic disease.
🧪 5 open trials
💊 7 approved treatments
🫀
Ovarian Cancer
PARP inhibitors, mirvetuximab ADC, and bevacizumab combinations. FRa and BRCA testing guide treatment. First OS benefit over chemotherapy now demonstrated.
🧪 5 open trials
💊 7 approved treatments
🫘
Kidney Cancer
Immunotherapy doublets now preferred over single-agent targeted therapy. Belzutifan (HIF-2a inhibitor) is a new drug class for ccRCC.
🧪 5 open trials
💊 7 approved treatments
🦋
Thyroid Cancer
RET, NTRK, BRAF, and IDH testing define treatment for advanced disease. Most thyroid cancers cured with surgery and radioiodine.
🧪 5 open trials
💊 7 approved treatments
🧠
Brain Cancer
IDH mutation, MGMT methylation, and H3 K27M define treatment. Vorasidenib FDA approved 2024 — landmark for IDH-mutated low-grade glioma.
🧪 5 open trials
💊 6 approved treatments
🫙
Liver Cancer
HCC. Sorafenib replaced after 13 years by immunotherapy combinations. STRIDE regimen offers bevacizumab-free IO option.
🧪 5 open trials
💊 6 approved treatments
🟫
Uterine / Endometrial
MMR/MSI testing mandatory. dMMR tumors dramatically benefit from immunotherapy. HER2 testing for serous subtype. ADC therapies expanding.
🧪 5 open trials
💊 6 approved treatments
🔵
Multiple Myeloma
BCMA CAR-T achieving 98% ORR. GPRC5D bispecific (Talvey) approved 2023. Multiple new drug classes for relapsed/refractory disease.
🧪 5 open trials
💊 7 approved treatments
🫶
Cervical Cancer
Pembrolizumab for PD-L1+ disease. Tisotumab vedotin first ADC to show OS superiority over chemotherapy in recurrent cervical cancer.
🧪 5 open trials
💊 5 approved treatments
Esophageal Cancer
HER2, PD-L1, CLDN18.2 testing mandatory. Nivolumab or pembrolizumab + chemotherapy standard first-line across all histologies.
🧪 5 open trials
💊 6 approved treatments
🫐
Gastric / Stomach Cancer
HER2, PD-L1, CLDN18.2, MSI — four biomarkers define treatment. Zolbetuximab FDA approved 2024 as first CLDN18.2-targeted therapy.
🧪 5 open trials
💊 6 approved treatments
🩺
Head & Neck Cancer
HPV status and PD-L1 CPS score guide first-line therapy. Pembrolizumab now standard. Tisotumab vedotin and LAG-3 inhibitors in advanced trials.
🧪 5 open trials
💊 6 approved treatments
🫁
Mesothelioma
Rare but aggressive cancer of the pleura and peritoneum, almost always linked to asbestos exposure. Nivolumab + ipilimumab now the frontline standard. BAP1, NF2, and CDKN2A drive emerging targeted approaches.
🧪 6 open trials
💊 4 approved treatments
Trials currently enrolling patients

Live data pulled from ClinicalTrials.gov. Every trial listed is actively recruiting. Search by cancer type or keyword below.

💡 Only about 7% of cancer patients enroll in clinical trials

Most patients who qualify never find out about trials they're eligible for. Your Cancer Path was built to change that. Reading this page is the first step.

🔍
Searches live ClinicalTrials.gov data in real time
🎯
Coming in the Full Version
We'll find recruiting trials that match you.

Right now you're searching manually — which is a great start. When the full site launches, you'll be able to create a free profile with your cancer type, stage, biomarkers, and treatment history. We'll automatically surface every actively recruiting trial you may qualify for and notify you when new ones open. No more hunting. The right trials will find you.

📍 Find Trials Near You

Enter your city to find actively enrolling trials within your area. Optionally filter by cancer type, drug name, or company. Results pull directly from ClinicalTrials.gov and include contact information for each site.

📍
How to access drugs
not yet FDA-approved.

The Right to Try Act (2018) and the FDA's Expanded Access program give seriously ill patients legal pathways to access investigational drugs. Here's exactly how to pursue them.

⚠️ Important Disclaimer

This guide is for informational and educational purposes only. It is not legal or medical advice. Your Cancer Path strongly recommends consulting with your oncologist and, where appropriate, a healthcare attorney before pursuing any of these pathways. Laws vary by state and situation.

🌍 Note for International Patients

The Right to Try Act and FDA Expanded Access programs described on this page are U.S.-specific legal pathways. If you are outside the United States, similar programs may exist in your country under different names and rules. For example, Health Canada administers the Special Access Program (SAP) for unapproved drugs. The European Medicines Agency (EMA) and individual EU member states have their own compassionate use frameworks. Australia's TGA offers the Special Access Scheme. The approval status, eligible indications, and available warnings for any given drug may also differ from what the FDA has approved. Please speak with an oncologist or specialist in your country who can advise on what pathways are available to you locally.

1

Confirm you meet the eligibility criteria

Under the Right to Try Act, you must: (a) have a life-threatening diagnosis confirmed by a licensed physician; (b) have tried all approved treatment options or be unable to participate in a clinical trial; (c) be unable to participate in a clinical trial for the drug you're seeking. Your physician must certify all of this in writing.

2

Identify the drug manufacturer and contact them directly

Under Right to Try, the request goes directly to the drug manufacturer — not to the FDA. You do not need FDA approval for this pathway. Search ClinicalTrials.gov for the drug sponsor's contact information. Many biotech companies have a "Compassionate Use" or "Medical Affairs" department specifically for these requests.

📄 Download: Sample Request Letter to Drug Manufacturer
3

Have your physician submit a written request

The manufacturer will require a letter from your treating physician confirming your diagnosis, treatment history, and why they support this request. Your doctor must also agree to monitor your treatment and report outcomes. Here is a script you can use to ask your doctor to write this letter.

📄 Download: Script for Talking to Your Doctor
4

Negotiate access and cost

Manufacturers are not required to provide the drug — they can say no. But many will say yes, especially if you're a good candidate who adds to their safety data. Insurance typically does not cover Right to Try drugs. Ask the manufacturer about patient assistance programs or compassionate pricing. Some patient advocacy groups can help fund this.

1

Understand the difference from Right to Try

Expanded Access involves the FDA directly. The FDA approves approximately 99% of Expanded Access requests, and the average review time for emergency requests is just 24 hours. For non-emergency requests, it is typically a few days to weeks. This pathway has more oversight but also more support.

2

Your physician submits FDA Form 3926

Your treating physician submits an Expanded Access request directly to the FDA. This is the form that allows an individual patient to access an unapproved drug. The FDA's Oncology Center of Excellence has a dedicated helpline: 1-855-5-CANCER (1-855-522-6237). Show your doctor this page and ask them to contact the FDA directly.

📄 Download: FDA Form 3926 (Individual Patient IND)
3

Manufacturer must also agree

Just like Right to Try, the drug manufacturer must agree to provide the drug. The FDA can approve the request but cannot force a company to provide its drug. Contact the manufacturer's Medical Affairs department in parallel with the FDA process.

4

Key contacts and resources

FDA Office of Oncology Products: [email protected]
FDA Expanded Access Navigator: expandedaccess.fda.gov
Patient Advocate Foundation: 1-800-532-5274
National Organization for Rare Disorders (NORD): 1-800-999-6673

💬

A script for your next appointment

Many doctors are unfamiliar with Right to Try or Expanded Access. Some may be hesitant. Here is language you can use:

"I've been researching [drug name] and I understand it's currently in Phase [X] trials with promising results for my diagnosis. I'd like to explore whether I might be a candidate for Right to Try or FDA Expanded Access. Would you be willing to look into submitting a request on my behalf? I can bring you the FDA Form 3926 and the manufacturer's contact information. This is important to me and I'd like your partnership in exploring it."

📄 Download: Personalized Doctor Conversation Guide
Real experiences.
Verified voices.

Share your journey. Read others. Ask questions. Every post is reviewed by a volunteer moderator — a cancer survivor — before it goes live. You are not alone.

🚀
Coming with the Full Launch
The community is coming. This is a preview.

When Your Cancer Path launches fully, this will be a live, moderated space where patients, survivors, and caregivers can share real experiences, ask hard questions, and find people who truly understand what they're going through. Every post will be reviewed by a volunteer moderator who has been through cancer themselves. For now, here's a preview of what it will look like.

Also launching with the full site
🎯

Personalized trial matching. Create a free profile with your cancer type, stage, and biomarkers — and we'll automatically surface every recruiting trial you may qualify for. No more searching manually. The right trials will find you, and you'll be notified when new ones open.

💬

A real survivor community. Ask questions, share your experience, and connect with people who've been through exactly what you're facing — all moderated by cancer survivors.

?
Share your experience when the community goes live.
📋 Topic tags will appear here
👁️ Preview only.  The posts below are examples of the kind of real, moderated conversations this community will host. Posting will be enabled at full launch.
K
✓ Survivor
I was diagnosed with cancer at 42, and I opted for surgery and I've been cancer-free for 16 years. But I remember the panic of those first weeks — searching the internet at 2am, finding conflicting information everywhere, not knowing what questions to ask my doctor. That's why this place exists. I built it for you. Ask anything. We'll do our best to help you find factual answers and connect you with people who've been through it.
M
Trial Participant
I'm currently enrolled in a Phase 2 trial for HER2+ breast cancer at UCLA. Three months in. I want to be honest — the process of getting into the trial was harder than I expected. My oncologist didn't know about it. I found it on ClinicalTrials.gov myself and brought the information to her. She was supportive once I showed her the data. The trial coordinator has been amazing. Happy to answer questions about what the enrollment process actually looks like from the inside.
R
Just finished my first cycle of FOLFOX. The fatigue is real. The neuropathy in my hands is something no one really warned me about. My oncologist was great but rushed — I wish someone had told me to ask specifically about cold sensitivity with oxaliplatin before I grabbed an ice-cold drink and felt like electric shocks in my fingers. Sharing this so someone else doesn't get surprised. Has anyone found anything that helped with the neuropathy?
Community Standards &
Terms of Participation

These rules exist to protect every person in this community. Please read them fully before participating.

⚖️ Attorney Review Notice: These community rules and terms have been drafted for attorney review prior to public launch. They are intentionally comprehensive to protect users, platform integrity, and legal compliance. If you are the attorney reviewing this document, please flag any sections requiring modification for HIPAA compliance, Section 230 protection, FDA disclaimer requirements, or state-specific regulations.

1. Purpose and Scope

Your Cancer Path is a research, education, and peer support platform for cancer patients, survivors, caregivers, and their families. It is not a medical practice, does not provide medical advice, and is not a substitute for consultation with a licensed physician or oncologist.

All information on Your Cancer Path is intended to help users become more informed participants in their own healthcare decisions — not to replace professional medical judgment.

Medical Disclaimer: Nothing on Your Cancer Path constitutes medical advice, diagnosis, or treatment recommendations. Always consult with your qualified healthcare provider before making any medical decisions. In a medical emergency, call 911 or go to your nearest emergency room.

2. Community Conduct Rules

All users — whether browsing anonymously or with an account — agree to the following standards when interacting with Your Cancer Path:

  • Be factual about your own experience. You may share what happened to you. You may not present your experience as applicable to others or as medical guidance.
  • Do not make medical claims about treatments. You may say "this drug made me feel X." You may not say "this drug cures cancer" or "this drug is better than what your doctor recommends."
  • No promotion of unproven or alternative cures. Claims that supplements, diets, spiritual practices, or unproven substances cure cancer will be removed. Sharing personal use of complementary therapies as part of your story is acceptable with appropriate framing.
  • No commercial promotion. You may not post affiliate links, promote products or services, advertise your practice or clinic, or solicit business of any kind.
  • Respect privacy. Never share another member's personal health information without explicit written consent. Do not attempt to identify anonymous users.
  • Be kind and constructive. Illness creates fear; fear creates sharpness. We ask for patience and empathy. Personal attacks, harassment, or bullying will result in immediate removal.
  • No misinformation. Do not post false or misleading information about treatments, clinical trials, or medical institutions. If you are unsure whether something is accurate, ask rather than assert.
  • No solicitation of personal contact outside the platform. Do not share your email, phone number, or solicit others' contact information in public posts. Use the platform's private messaging feature when available.

3. Moderation System

All posts submitted to Your Cancer Path go into a moderation queue before becoming publicly visible. Posts are reviewed by trained volunteer moderators — all of whom are cancer survivors or caregivers with lived experience.

Automated Red Flag System: Our platform uses keyword and pattern detection to pre-categorize posts:

  • 🔴 Red Flag (Auto-Hold, Priority Review): Posts containing miracle cure language, specific product promotion, pricing for medical services, claims that a drug "cures" any cancer, or references to obtaining prescription drugs illegally.
  • 🟡 Yellow Flag (Human Review Required): Posts containing strong efficacy claims about specific named drugs, references to Right to Try or off-label use, discussion of clinical trial access outside of enrollment, or emotionally intense content that may require sensitivity review.
  • 🟢 Green (Standard Queue): Personal experience sharing, questions to the community, emotional support, and general discussion.
Moderator Note: Volunteer moderators are empowered to Approve, Reject, or Escalate to a senior moderator or the Your Cancer Path team. Moderators are not medical professionals and do not evaluate medical accuracy — they evaluate compliance with community standards. Medical accuracy is handled at the platform content level by our medical advisory board.

4. Content Accuracy Standards

Treatment information, clinical trial data, drug efficacy figures, and side effect profiles published by Your Cancer Path on its treatment and trial pages are sourced exclusively from:

  • U.S. Food and Drug Administration (FDA) approved drug labeling and approval announcements
  • ClinicalTrials.gov trial registration data
  • Peer-reviewed published clinical trial results
  • National Cancer Institute (NCI) data
  • Published prescribing information (package inserts)

Your Cancer Path does not publish editorial opinions on treatment effectiveness. Where data conflicts between sources, we note the conflict and cite all sources. All content pages display their last review date and data source.

5. Trial Matching & Opt-In Data

Users who create an account and opt in to trial matching agree to the following:

  • Their profile data (cancer type, stage, treatment history, location) may be used to identify relevant clinical trial matches.
  • Matched trial sponsors may contact them through the Your Cancer Path platform only — personal contact information is never shared with third parties.
  • The opt-in can be removed at any time by updating account preferences.
  • Your Cancer Path does not sell personal health data. Sponsors pay for platform access, not individual data records.
  • All data is stored in HIPAA-compliant encrypted systems. [Attorney: Please review our data practices document separately for HIPAA compliance certification.]

6. Consequences of Violations

  • First violation: Post removed, private warning issued to account holder.
  • Second violation: Post removed, 7-day account suspension, written warning.
  • Third violation: Permanent account ban. Device and IP flagged.
  • Immediate permanent ban (no warnings): Promotion of illegal drug acquisition, harassment or threats, intentional medical misinformation likely to cause harm, sharing another user's private health information without consent, commercial spam or affiliate marketing.
Zero Tolerance: Any post that a reasonable person would interpret as promoting self-harm, discouraging evidence-based medical treatment in favor of unproven alternatives, or creating imminent risk of patient harm will result in immediate removal and permanent ban without appeal.

7. Volunteer Moderator Standards

Volunteer moderators agree to additional standards:

  • Review posts only against community standards — not personal medical opinion.
  • Maintain strict confidentiality of all content reviewed in the queue.
  • Escalate any post that raises a question of user safety, medical emergency, or platform liability.
  • Recuse themselves from reviewing posts from people they know personally.
  • Complete Your Cancer Path moderator training before reviewing any posts.
  • Commit to a minimum of 3 hours per week review time.

8. Right to Try & Expanded Access Content

Your Cancer Path provides educational guides on Right to Try and FDA Expanded Access. This content is:

  • Informational only — not legal or medical advice.
  • Sourced from the FDA, Right to Try Act (21 U.S.C. § 360bbb-0a), and official government resources.
  • Not an endorsement of any specific drug, manufacturer, or access pathway.

Your Cancer Path does not facilitate or arrange drug access on behalf of any user. We provide information to help patients advocate for themselves in partnership with their treating physician.

⚖️ Attorney Review — Terms of Service: The following Terms of Service are drafted for attorney review. Sections marked [ATTORNEY NOTE] require jurisdiction-specific review, including Section 230 applicability, HIPAA compliance, FDA disclaimer adequacy, California Consumer Privacy Act (CCPA) conformance, and enforceability of limitation of liability and arbitration clauses.

9. Terms of Service — Acceptance and Eligibility

By accessing or using Your Cancer Path (the "Platform"), whether as an anonymous visitor, registered user, community member, volunteer moderator, or any other capacity, you ("User") agree to be bound by these Terms of Service ("Terms"), our Privacy Policy, and our Community Rules, all of which are incorporated herein by reference.

If you do not agree to these Terms in their entirety, you must immediately discontinue use of the Platform. Your Cancer Path reserves the right to modify these Terms at any time. Continued use of the Platform following notice of modification constitutes acceptance of the revised Terms.

  • Age Requirement: You must be at least 13 years of age to use the Platform. Users under 18 must have parental or guardian consent. Your Cancer Path does not knowingly collect personal information from children under 13.
  • Geographic Scope: The Platform is operated from the United States. Users accessing the Platform from outside the United States do so at their own risk and are responsible for compliance with local laws.
  • Capacity: By using the Platform, you represent that you have the legal capacity to enter into binding agreements under applicable law.

10. Intellectual Property Rights

The Your Cancer Path name, compass rose logo, tagline "Find Clarity. Move Forward.", platform design, source code, written content, community guidelines, treatment data organization and presentation methodology, trial matching system, and all other original content on the Platform are the exclusive intellectual property of Your Cancer Path and its founder, Kelly Foy, protected by United States and international copyright, trademark, and trade secret laws.

Prohibited Conduct: You may not copy, reproduce, scrape, redistribute, create derivative works from, reverse engineer, sell, license, or otherwise exploit any portion of the Platform or its content without express prior written permission from Your Cancer Path. This prohibition applies to the Platform's design, code, written content, data organization, and community infrastructure — in whole or in part.

User-submitted content (posts, comments, testimonials) remains the intellectual property of the submitting user. By submitting content to the Platform, you grant Your Cancer Path a perpetual, worldwide, royalty-free, non-exclusive license to use, display, reproduce, and distribute such content in connection with operating and promoting the Platform, including in anonymized and aggregated research and marketing materials.

[ATTORNEY NOTE: Confirm DMCA safe harbor compliance, counter-notification procedures, and designated agent registration with Copyright Office.]

11. Privacy, Data Collection, and HIPAA

Your Cancer Path collects the following categories of information:

  • Anonymous browsing: Standard server logs, aggregate analytics. No personally identifiable information collected.
  • Registered users: Username, email address, cancer type, disease stage, treatment status, and geographic region (state/region only).
  • Opted-in users: All of the above plus additional health profile information voluntarily provided for trial matching purposes.
  • Community contributors: User-submitted posts, comments, and media, associated with your account.

Your Cancer Path treats all health-related user data as protected health information (PHI) and implements HIPAA-compliant administrative, physical, and technical safeguards. We do not sell your personal data. We do not share your personal contact information with pharmaceutical sponsors or any third party without your explicit consent. Sponsors may contact opted-in users only through the Platform's internal messaging system.

You have the right to access, correct, export, and delete your personal data at any time through your account settings. Requests can also be submitted to [email protected].

[ATTORNEY NOTE: Review full CCPA compliance requirements for California users, including opt-out rights, data deletion timelines, and annual disclosure obligations. Confirm HIPAA covered entity vs. business associate status. Prepare full Privacy Policy as a separate document.]

12. Clinical Trial Opt-In and Sponsor Matching

The trial matching and opt-in contact feature operates as follows:

  • Participation in trial matching is entirely voluntary. You may opt in or out at any time through your account settings.
  • By opting in, you authorize Your Cancer Path to share your anonymized health profile (cancer type, stage, treatment history, geographic region) with vetted clinical trial sponsors for the sole purpose of evaluating your potential eligibility for clinical trials.
  • Sponsors may send you a single introductory message through the Platform's internal messaging system. You control all further contact and may block any sponsor at any time.
  • Your Cancer Path charges sponsors a platform access fee. You are never charged for trial matching. Your Cancer Path does not receive compensation based on whether you enroll in a trial.
  • Trial matching is not a guarantee of eligibility, enrollment, or medical benefit. Eligibility is determined solely by the trial sponsor and your treating physician.
  • Your Cancer Path is not a healthcare provider, clinical research organization, or patient recruitment agency. We are an information and community platform that facilitates connections between willing patients and vetted researchers.

[ATTORNEY NOTE: Review FDA regulations on patient recruitment advertising (21 C.F.R. Part 312), FTC endorsement guidelines, and state-specific patient brokering laws. Confirm sponsor vetting standards and contractual requirements for platform access.]

13. Disclaimer of Warranties and Limitation of Liability

IMPORTANT — READ CAREFULLY: The Platform and all content, information, tools, features, and services provided thereon are offered "AS IS" and "AS AVAILABLE" without warranty of any kind, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, accuracy, completeness, or non-infringement.

Your Cancer Path does not warrant that:

  • Treatment information, clinical trial listings, drug efficacy data, or side effect profiles are complete, current, or applicable to your specific medical situation;
  • The Platform will be uninterrupted, error-free, or free of viruses or other harmful components;
  • Any clinical trial you learn about through the Platform will accept you as a participant or produce a medical benefit;
  • Community member posts or testimonials are accurate, complete, or medically reliable.

To the maximum extent permitted by applicable law, Your Cancer Path, its founder, officers, advisors, moderators, and affiliates shall not be liable for any indirect, incidental, special, consequential, punitive, or exemplary damages arising from your use of or inability to use the Platform, including but not limited to medical decisions made in reliance on Platform content, loss of data, or unauthorized access to your account.

Your Cancer Path's total cumulative liability to you for any claim arising from these Terms or your use of the Platform shall not exceed the greater of: (a) the total fees paid by you to Your Cancer Path in the twelve months preceding the claim, or (b) one hundred dollars ($100.00).

[ATTORNEY NOTE: Confirm enforceability of liability cap under California law. Review consumer protection statutes that may limit disclaimer enforceability for health-related platforms.]

14. Indemnification

You agree to indemnify, defend, and hold harmless Your Cancer Path, its founder Kelly Foy, medical advisors, volunteer moderators, employees, contractors, and agents from and against any claims, liabilities, damages, losses, costs, and expenses (including reasonable attorneys' fees) arising out of or related to: (a) your use of the Platform; (b) your violation of these Terms; (c) your violation of any third-party rights, including intellectual property, privacy, or publicity rights; (d) any content you submit to the Platform; or (e) any medical decision you make based on information found on the Platform.

15. Governing Law, Arbitration, and Class Action Waiver

These Terms shall be governed by the laws of the State of California without regard to conflict of law principles. Any dispute arising from or relating to these Terms or your use of the Platform shall be resolved by binding arbitration administered by the American Arbitration Association under its Consumer Arbitration Rules, except that either party may seek injunctive or other equitable relief in any court of competent jurisdiction to protect intellectual property or confidential information.

Class Action Waiver: You agree that any arbitration shall be conducted solely on an individual basis and not as a class, collective, or representative action. You expressly waive your right to participate in any class action lawsuit or class-wide arbitration against Your Cancer Path.

[ATTORNEY NOTE: Review enforceability of mandatory arbitration and class action waiver under California law, including PAGA claims for employees. Confirm AAA Consumer Arbitration Rules are appropriate and that filing fees do not create unconscionability concerns.]

16. Section 230 and User-Generated Content

Your Cancer Path is an interactive computer service as defined under 47 U.S.C. § 230 (the Communications Decency Act). Your Cancer Path is not the publisher or speaker of user-generated content posted by community members and is not liable for such content to the extent permitted by Section 230. Your Cancer Path's moderation activities, including reviewing, approving, rejecting, or removing content, do not constitute editorial control that would eliminate Section 230 protections.

However, Your Cancer Path does not rely solely on Section 230 as a shield. We proactively moderate all content before publication to protect our community, and we will cooperate with law enforcement and regulatory authorities in response to lawful requests regarding Platform content.

[ATTORNEY NOTE: Confirm current Section 230 jurisprudence in the Ninth Circuit and any pending legislative changes. Review whether health-specific platforms face additional exposure under state consumer protection or health information statutes.]

17. Donations, Memberships, and Financial Transactions

Your Cancer Path accepts voluntary donations and Founding Member fees to support platform operations. All financial transactions are processed through third-party payment processors. Your Cancer Path does not store payment card information.

  • Founding Memberships are one-time, lifetime payments that unlock premium features. They are non-refundable except where required by applicable law.
  • Donations are voluntary contributions and are non-refundable. Whether donations are tax-deductible depends on Your Cancer Path's current tax status, which will be disclosed at the time of donation.
  • Angel and Visionary contributions are subject to separate written agreements. Contact [email protected] for details.

[ATTORNEY NOTE: Review IRS regulations on charitable solicitation, state charitable solicitation registration requirements (many states require registration before soliciting donations), and FTC endorsement rules for testimonials used in fundraising.]

18. Contact and Notices

All legal notices, attorney correspondence, DMCA takedown requests, privacy requests, and general inquiries should be directed to:

  • Email: [email protected]
  • Founder: Kelly Foy, Your Cancer Path
  • Location: Santa Ynez Valley, California
  • Website: yourcancerpath.com

Your Cancer Path will respond to properly submitted legal notices within 10 business days. For urgent matters involving user safety or potential harm, please indicate "URGENT" in your subject line.

Last Updated: April 2026 (Pre-Launch Draft — Pending Attorney Review)
Effective Date: Upon public launch (TBD)
Version: 1.0 MVP Draft

These Terms, Community Rules, and Privacy Policy collectively constitute the complete legal framework governing use of Your Cancer Path. Your Cancer Path reserves the right to update these documents at any time. Users will be notified of material changes via email (registered users) and platform banner notice (all users).

Built for my friend.
And for everyone who deserves better than what the system gave him.
"I've had my own experience with cancer. Years ago I faced a diagnosis that shook my world and opened my eyes to how hard it is to navigate the medical system when you're scared and don't know what questions to ask. I survived. I consider myself one of the lucky ones. But it was losing a close friend to cancer this past November that became the real catalyst behind Your Cancer Path."
The Founder, Your Cancer Path  ·  Cancer Survivor  ·  In memory of a friend who deserved more

He was someone I genuinely liked and admired — we first crossed paths in the 1990s, and when I found out about his diagnosis, something in me just couldn't stand by. I was determined to help him find every option available — not just the standard path, but everything. Clinical trials. Experimental drugs. Expanded Access. Right to Try. I believed then, and I believe now, that there were options worth exploring that might have given him more time.

What I found instead was a wall — not built by any one person, but by a system with layers of complexity that most patients and families have no idea exist.

He went through chemotherapy. He tried a targeted radiation therapy that made him miserable — the side effects were severe, and there were stretches where he was essentially confined to home because of how his body responded. He lost feeling in his feet. He was exhausted and in pain. And through all of it, he kept fighting.

I worked closely with him and his wife. I went to doctor's appointments with them. I tried to help navigate a path toward an investigational drug — one the manufacturer was willing and ready to provide. The drug company said yes. There was no guarantee it would have worked. But we wanted the chance to try.

What we ran into was the reality of how complex these pathways are. The paperwork. The liability concerns. The way our medical system is structured around standard of care — for reasons that aren't always wrong, but that can leave patients without options when time is short. His physician had real concerns, including around malpractice coverage, and I came to understand that those concerns are part of a bigger, broken system — not a reflection of any one doctor's heart. But in the moment, it felt like a door closing.

His wife didn't know these pathways existed. My friend didn't know. Most people don't — because nobody tells them. I reached out to physicians across the country trying to find someone who could help us move forward. A few pointed us in directions that required steps we couldn't complete in time.

My friend fought with everything he had. In the end, the cancer spread to his brain, his lungs, his entire body. He passed away in November. He is out of pain now. But I carry the weight of knowing that information and access existed that he never got to — and that we just couldn't connect him to it in time.

Your Cancer Path exists because of him. It exists for the patient who was just diagnosed and doesn't yet know what the road ahead might look like — what the diagnostic process involves, what questions to ask, and what options exist before treatment even begins. It exists for the patient already in treatment who wonders whether there is something else worth trying. It exists so that every patient — and their spouse, and their family — walks into every appointment knowing every option on the table. So they know what a clinical trial is and how to find one. So they know what Expanded Access means and how to start that conversation with their doctor. So they know that if one door closes, there may be others worth knocking on. I am not a doctor. This platform is not medical advice. But it is here, and it is free, and no one should have to navigate this alone.

Our Mission

To put factual, comprehensive, plain-English cancer treatment information in the hands of every patient and family who needs it — free, anonymous, and without agenda — so they can have better conversations with their doctors and find the right path faster.

Our Commitment

Your Cancer Path is independently operated. Pharma sponsors pay to reach our opted-in community — they do not pay to shape what we publish. Every fact is cited. Every source is disclosed. Our medical advisory board reviews all clinical content independently.

Stay Connected
Your Cancer Path is free. Always.
Browse every treatment, trial, and guide — no account needed, no sign-up, completely anonymous. We're currently in beta. If you'd like to stay informed about the full launch, share feedback, or learn about investment opportunities, we'd love to hear from you.
Three Ways to Give

Choose what
feels right.

Your Cancer Path operates as two parallel entities — a technology company building the platform, and a nonprofit foundation ensuring free access for every patient who needs it. Your support funds both.

🏛️
How We're Structured

Your Cancer Path operates as two connected entities: Your Cancer Path Inc. (the tech company that builds and maintains the platform) and Your Cancer Path Foundation (the nonprofit that funds free access for patients who can't afford anything). Founding Memberships and Build Faster contributions go to the tech company. Fund a Fighter donations go directly to the nonprofit foundation. Full financial transparency is published quarterly.

🏥 Nonprofit Foundation
🤝
Fund a Fighter
Every dollar you give goes directly to the Your Cancer Path Foundation — keeping the platform free for patients who can't afford a premium service. When you give, you're not donating to a company. You're handing a compass to someone sitting alone in a guest room at midnight, scared and searching.
Select an amount
  • 100% goes to the nonprofit foundation — zero to platform operations
  • Tax-deductible once 501(c)(3) status is granted (in process)
  • Funds free access for patients, caregivers, and families
  • Optional: leave a dedication in memory of someone you love

Processed securely via Stripe. Receipt emailed automatically.

🏗️
Help Us Build Faster
Be specific with your support. Every dollar here goes directly to the infrastructure that makes Your Cancer Path trustworthy — attorney review, medical advisory fees, adding new cancer types, and technical development. We publish exactly how every dollar is spent.
$500
💼 One attorney review session — keeping the legal framework current and compliant
$1,000
🏥 One month of medical content review — an oncologist checks our work
$5,000
🧬 One new cancer type added to the platform — full treatments, trials, and pathways
$10,000
🌐 Three months of full development — new features, faster infrastructure, wider reach

Goes to Your Cancer Path Inc. (the tech company). Supports platform operations and growth.

Full Transparency

Your Cancer Path Foundation (Nonprofit)
  • • Free access funding for patients
  • • 501(c)(3) application in progress
  • • Quarterly financial reports published
  • • Zero admin overhead from Fund a Fighter donations
Your Cancer Path Inc. (Tech Company)
  • • Platform development and maintenance
  • • Attorney and medical advisory fees
  • • Founding Member benefits and features
  • • Portion donated to Foundation per membership
"I built this because I wish it had existed when my friend needed it. I'm one person. Every contribution — even a small one — means I can justify spending more hours on research, more cancer types, more pathways. It means someone somewhere finds the answer they needed. That's the whole point."
— Kelly Foy, Founder · Your Cancer Path · Santa Ynez Valley, California
Beta Preview

Stay connected.
Be part of what's coming.

Your Cancer Path is currently in beta. Whether you're a patient, caregiver, medical professional, or potential partner — we'd love to stay in touch as we build toward full launch.

⚠️
Beta Preview — Not Yet Public

The content on Your Cancer Path has not yet been reviewed by a licensed medical professional. All information is sourced from the FDA, ClinicalTrials.gov, and peer-reviewed publications, but please treat this as a starting point for conversations with your oncologist — not a substitute for professional medical advice.

Stay Connected with Your Cancer Path

Fill out the form below and we'll be in touch. We read every submission personally.

We respect your privacy. Your information will never be sold or shared. You can unsubscribe at any time.

Posts Pending Review

Review each post against community standards. Approve, reject, or escalate. You are not evaluating medical accuracy — only compliance with community rules.

Submitted 14 min ago · Prostate Cancer · Anonymous
Topic: Treatment Experience
🟡 Yellow Flag
"I used leronlimab off-label through a doctor in Mexico. My PSA dropped significantly after 3 months. I think everyone should know about this option. My doctor here in the US wouldn't prescribe it but I found a way to get it."
Flag reason: References obtaining a drug outside normal access channels, strong efficacy claim, and language that may encourage others to seek drugs illegally. Recommend escalation or rejection with personal experience reframe option.
Submitted 32 min ago · Breast Cancer · MargaretT
Topic: Clinical Trial Experience
🟢 Green
"Just completed month 4 of my Phase 2 trial. The fatigue has been manageable. The coordinator calls me every week. I feel like someone is actually paying attention to how I'm doing. For anyone considering a trial — the support structure is often better than standard of care in my experience."
Submitted 1 hr ago · Colorectal · Anonymous
Topic: General
🔴 Red Flag
"I cured my stage 4 colorectal cancer completely with high-dose vitamin C infusions and a ketogenic diet. My oncologist is shocked. I stopped all chemo 6 months ago. Anyone interested in more info, DM me, I sell a protocol guide for $197."
Flag reason: Miracle cure claim, commercial solicitation, discouragement of evidence-based treatment, off-platform contact solicitation. Recommend immediate rejection. Permanent ban review triggered.
🔒 Early Preview
Beta Preview — Medical content has not yet been reviewed by a licensed physician. Use this as a starting point for conversations with your oncologist — not a substitute for professional medical advice.
🧭
Welcome to Your Cancer Path
This is a beta preview of Your Cancer Path — a free platform built to help cancer patients and their families navigate treatment options and clinical trials.

Important: Content on this site is sourced from the FDA and ClinicalTrials.gov but has not yet been reviewed by a licensed medical professional. Everything here is intended to help you have better conversations with your oncologist — not to replace professional medical advice.
By continuing you acknowledge this is an informational resource only. Always consult your oncologist before making medical decisions.
Beta Preview — Medical content has not yet been reviewed by a licensed physician. Use this as a starting point for conversations with your oncologist — not a substitute for professional medical advice.